{"id":"W4405222141","doi":"10.1093/brain/awae308","title":"Optimizing rare disorder trials: a phase 1a/1b randomized study of KL1333 in adults with mitochondrial disease","year":2024,"lang":"en","type":"article","venue":"Brain","topic":"Genomics and Rare Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Wellcome Trust Centre for Mitochondrial Research; NIHR Newcastle Biomedical Research Centre; Medical Research Council; Centro Singular de Investigación de Galicia; Rosetrees Trust; University College London Hospitals NHS Foundation Trust; NIHR Barts Biomedical Research Centre, Queen Mary University of London; Medical Research Council Canada; Newcastle University; University College London; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Lily Foundation; Muscular Dystrophy UK; Department of Health and Social Care; Wellcome Trust","keywords":"Tolerability; Clinical trial; Mitochondrial disease; Medicine; Orphan drug; Disease; Drug development; Randomized controlled trial; Physical therapy; Internal medicine; Bioinformatics; Drug; Adverse effect; Pharmacology; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004550513,0.0001857121,0.0005039299,0.0001025395,0.00003261636,0.00004222941,0.0001399711,0.000060663,0.00003136208],"category_scores_gemma":[0.0007051382,0.0001314308,0.0002156461,0.0001371028,0.00006542059,0.000004872665,0.00006677676,0.00006783701,0.000001925056],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000008034154,"about_ca_system_score_gemma":0.0001758468,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007130444,"about_ca_topic_score_gemma":0.0001665327,"domain_scores_codex":[0.998391,0.0004070535,0.0004559565,0.0004253865,0.0001372965,0.0001832603],"domain_scores_gemma":[0.999298,0.0001654389,0.00009374924,0.0002858162,0.00004277956,0.0001142037],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9097191,0.009043875,0.0005855265,0.0006758176,0.001417458,0.0009226298,0.006360836,0.00302258,0.04505136,0.0002536083,0.005467282,0.01747994],"study_design_scores_gemma":[0.9673817,0.003238569,0.0002768987,0.0008134937,0.0006725234,0.00001459596,0.005784814,0.005059815,0.002158901,0.0002356886,0.01341825,0.000944803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900968,0.006830428,0.0007716493,0.0002330484,0.0002143693,0.001615278,0.0001511424,0.00001462507,0.00007265055],"genre_scores_gemma":[0.9985786,0.000129273,0.0002747812,0.00006320533,0.0002343525,0.0002476837,0.0002248224,0.00003171746,0.0002155678],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05766257,"threshold_uncertainty_score":0.5359593,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01134214685043658,"score_gpt":0.2968644397288556,"score_spread":0.285522292878419,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}